文献速递类风湿关节炎

非甾体抗炎药使用者重大毒性风险评分的推导与验证

Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2019-06-12

基于随机对照试验数据,在已知心血管疾病或危险因素且患骨关节炎或类风湿关节炎的NSAID使用者中推导并验证1年重大毒性风险评分;验证队列C指数0.73,总队列0.71,模型校准良好;总人群(n=23,735)中4.6%预测风险<1%,68.6%为1-4%,26.9%>4%。

要点

  • 风险评分可预测NSAID使用者1年重大毒性,验证队列C指数0.73。
  • 预测变量包括年龄、男性、心血管病史、高血压、糖尿病等。
  • 总人群中26.9%预测1年重大毒性风险>4%。

核心结论

  • 风险评分能准确对NSAID使用者1年重大毒性风险进行分层,可能有助于识别可安全使用这些药物的患者。

研究设计与样本

  • 基于随机对照试验数据,将已知心血管疾病或危险因素且患骨关节炎或类风湿关节炎的患者分为推导队列和验证队列,随机接受塞来昔布、萘普生或布洛芬常规剂量治疗。

主要发现

  • 推导队列中与重大毒性显著相关的变量包括年龄、男性、心血管病史、高血压、糖尿病、吸烟、他汀使用、血清肌酐升高、血细胞比容水平和关节炎类型。
  • 验证队列C指数为0.73,总队列为0.71,模型校准良好。
  • 总人群(n=23,735)中1,080例(4.6%)预测1年重大毒性风险<1%,16,273例(68.6%)为1-4%,6,382例(26.9%)>4%。

关键数值与推荐

  • 风险评分预测NSAID使用者1年重大毒性,包括主要不良心血管事件、急性肾损伤、显著胃肠道事件和死亡。
  • 验证队列C指数0.73,总队列C指数0.71。
  • 总人群(n=23,735)中预测1年风险<1%者占4.6%,1-4%者占68.6%,>4%者占26.9%。

临床怎么用

  • 可用于风湿免疫科评估NSAID使用者1年重大毒性风险,辅助识别可安全使用NSAID的患者。

局限性

  • 研究基于随机对照试验人群,外部适用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used in rheumatology, they can cause major toxicity. Improving the risk/benefit ratio requires a more precise understanding of risk. This study was undertaken to derive and validate a risk score for major toxicity among NSAID users enrolled in a randomized controlled trial. METHODS: Patients enrolled in a randomized controlled trial who had known cardiovascular disease or risk factors as well as osteoarthritis or rheumatoid arthritis were divided into derivation and validation cohorts. Patients were randomized to receive celecoxib, naproxen, or ibuprofen at typical dosages. The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality. Variables significantly associated with major toxicity were candidates for inclusion in the final regression model. After derived models were found to have a similar model fit in the validation set, the cohorts were combined, allowing calculation of a risk score. RESULTS: In the derivation cohort, significant variables included age, male sex, history of cardiovascular disease, hypertension, diabetes mellitus, tobacco use, statin use, elevated serum creatinine level, hematocrit level, and type of arthritis. The C-index was 0.73 in the validation cohort and 0.71 in the total cohort; the model was well calibrated. Of the total population with complete data (n = 23,735), 1,080 participants (4.6%) had a predicted 1-year risk of major toxicity of <1%, 16,273 (68.6%) had a predicted risk of 1-4%, and 6,382 (26.9%) had a predicted risk of >4%. CONCLUSION: The risk score accurately categorizes the 1-year risk of major toxicity among NSAID users and may be useful in identifying patients who can safely use these agents.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Solomon DH, Shao M, Wolski K, et al. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis Rheumatol. 2019. PMID: 30801994. doi:10.1002/art.40870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。